Effects  	Effects  	 NNS	O
of  	of  	 IN	O
paliperidone  	paliperidone  	 JJ	O
extended  	extended  	 JJ	O
release  	release  	 NN	O
on  	on  	 IN	O
functioning  	functioning  	 VBG	B-NP
level  	level  	 NN	I-NP
and  	and  	 CC	O
symptoms  	symptoms  	 NNS	B-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
recent  	recent  	 JJ	O
onset  	onset  	 NN	B-NP
schizophrenia 	schizophrenia 	 NN	I-NP
:  	:  	 :	O
An  	An  	 DT	O
open-label 	open-label 	 JJ	B-NP
,  	,  	 ,	O
single-arm 	single-arm 	 NNP	B-NP
,  	,  	 ,	O
flexible-dose 	flexible-dose 	 NNP	B-NP
,  	,  	 ,	O
12-months  	12-months  	 CD	O
follow-up  	follow-up  	 JJ	B-NP
study  	study  	 NN	I-NP
Response  	Response  	 NNP	I-NP
to  	to  	 TO	O
antipsychotic  	antipsychotic  	 VB	O
treatment  	treatment  	 NN	O
is  	is  	 VBZ	O
better  	better  	 JJR	O
in  	in  	 IN	O
the  	the  	 DT	O
early  	early  	 JJ	O
stages  	stages  	 NNS	O
of  	of  	 IN	O
schizophrenia 	schizophrenia 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
primary  	primary  	 JJ	B-NP
objective  	objective  	 NN	I-NP
of  	of  	 IN	O
this  	this  	 DT	O
non-randomized 	non-randomized 	 JJ	B-NP
,  	,  	 ,	O
single-arm 	single-arm 	 NNP	B-NP
,  	,  	 ,	O
multicenter  	multicenter  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
trial  	trial  	 NN	I-NP
was  	was  	 VBD	O
to  	to  	 TO	O
explore  	explore  	 VB	O
the  	the  	 DT	O
response  	response  	 NN	O
to  	to  	 TO	O
treatment  	treatment  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
flexible  	flexible  	 JJ	O
dose  	dose  	 NN	O
of  	of  	 IN	O
paliperidone  	paliperidone  	 NNS	B-NP
( 	( 	 -LRB-	O
mean  	mean  	 NN	B-NP
=  	=  	 SYM	O
6.42  	6.42  	 FW	O
mg 	mg 	 FW	B-NP
/ 	/ 	 FW	I-NP
day 	day 	 NN	I-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
recent  	recent  	 JJ	O
onset  	onset  	 NN	B-NP
schizophrenia  	schizophrenia  	 NN	I-NP
(  	(  	 -LRB-	O
< 	< 	 SYM	O
3  	3  	 CD	O
years  	years  	 NNS	O
after  	after  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
episode 	episode 	 NN	B-NP
/ 	/ 	 CD	I-NP
hospitalization 	hospitalization 	 NN	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Severity  	Severity  	 NN	O
of  	of  	 IN	O
clinical  	clinical  	 JJ	B-NP
symptoms  	symptoms  	 NNS	I-NP
was  	was  	 VBD	O
evaluated  	evaluated  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
Positive  	Positive  	 JJ	B-NP
and  	and  	 CC	I-NP
Negative  	Negative  	 NNP	I-NP
Syndrome  	Syndrome  	 NNP	I-NP
Scale  	Scale  	 NNP	I-NP
( 	( 	 -LRB-	O
PANSS 	PANSS 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
functioning  	functioning  	 VBG	O
was  	was  	 VBD	O
assessed  	assessed  	 VBN	O
using  	using  	 VBG	O
the  	the  	 DT	O
Global  	Global  	 NNP	B-NP
Assessment  	Assessment  	 NNP	I-NP
of  	of  	 IN	I-NP
Functioning  	Functioning  	 NNP	I-NP
( 	( 	 -LRB-	O
GAF 	GAF 	 NNP	B-NP
)  	)  	 -RRB-	O
scale  	scale  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
Personal  	Personal  	 JJ	B-NP
and  	and  	 CC	I-NP
Social  	Social  	 NNP	I-NP
Performance  	Performance  	 NNP	I-NP
Scale  	Scale  	 NNP	O
( 	( 	 -LRB-	O
PSP 	PSP 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
a  	a  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
85  	85  	 CD	O
patients  	patients  	 NNS	O
enrolled 	enrolled 	 VBD	O
,  	,  	 ,	O
80  	80  	 CD	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
eligible 	eligible 	 JJ	O
.  	.  	 .	O
Total  	Total  	 JJ	B-NP
PSP  	PSP  	 NNP	I-NP
score  	score  	 NN	I-NP
at  	at  	 IN	O
baseline  	baseline  	 NN	B-NP
( 	( 	 -LRB-	O
50.2  	50.2  	 CD	O
±  	±  	 CD	O
11.6 	11.6 	 CD	O
)  	)  	 -RRB-	O
increased  	increased  	 VBD	O
at  	at  	 IN	O
all  	all  	 DT	O
visits 	visits 	 NNS	O
.  	.  	 .	O
Total  	Total  	 JJ	B-NP
PSP  	PSP  	 NNP	I-NP
score  	score  	 NN	I-NP
was  	was  	 VBD	O
65.4  	65.4  	 CD	O
±  	±  	 CD	O
12.1  	12.1  	 CD	O
at  	at  	 IN	O
month  	month  	 NN	O
12  	12  	 CD	O
( 	( 	 -LRB-	O
P  	P  	 NNP	O
< 	< 	 SYM	O
0.001 	0.001 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
GAF  	GAF  	 NNP	B-NP
scores  	scores  	 NNS	I-NP
were  	were  	 VBD	O
significantly  	significantly  	 RB	O
higher  	higher  	 JJR	O
at  	at  	 IN	O
all  	all  	 DT	O
visits  	visits  	 NNS	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
baseline  	baseline  	 NN	B-NP
( 	( 	 -LRB-	O
P  	P  	 NN	O
=  	=  	 SYM	O
0.001 	0.001 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
It  	It  	 PRP	O
was  	was  	 VBD	O
62.4  	62.4  	 CD	O
±  	±  	 CD	O
12.5  	12.5  	 CD	O
with  	with  	 IN	O
an  	an  	 DT	O
increase  	increase  	 NN	O
of  	of  	 IN	O
42.9 	42.9 	 CD	O
%  	%  	 NN	O
at  	at  	 IN	O
month  	month  	 NN	O
12  	12  	 CD	O
( 	( 	 -LRB-	O
P  	P  	 NNP	O
< 	< 	 SYM	O
0.001 	0.001 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
PANSS  	PANSS  	 NNP	B-NP
Positive  	Positive  	 NNP	I-NP
and  	and  	 CC	O
Negative  	Negative  	 JJ	B-NP
subscales  	subscales  	 NN	I-NP
and  	and  	 CC	O
General  	General  	 NNP	O
psychopathology  	psychopathology  	 VBD	O
subscale  	subscale  	 JJ	B-NP
scores  	scores  	 NNS	I-NP
showed  	showed  	 VBD	O
significant  	significant  	 JJ	O
reductions  	reductions  	 NNS	O
beginning  	beginning  	 VBG	O
with  	with  	 IN	O
month  	month  	 NN	O
3  	3  	 CD	O
and  	and  	 CC	O
were  	were  	 VBD	O
11.9  	11.9  	 CD	O
±  	±  	 CD	O
3.8  	3.8  	 CD	O
( 	( 	 -LRB-	O
29.3 	29.3 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
P  	P  	 NNP	O
< 	< 	 SYM	O
0.001 	0.001 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
13.7  	13.7  	 CD	O
±  	±  	 CD	O
5.6  	5.6  	 CD	O
( 	( 	 -LRB-	O
27.3 	27.3 	 NNP	O
%  	%  	 NN	O
P  	P  	 NN	O
< 	< 	 SYM	O
0.001 	0.001 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
27.8  	27.8  	 CD	O
±  	±  	 CD	O
7.1  	7.1  	 CD	O
( 	( 	 -LRB-	O
23.2 	23.2 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
P  	P  	 NNP	O
< 	< 	 SYM	O
0.001 	0.001 	 NNP	O
)  	)  	 -RRB-	O
at  	at  	 IN	O
month  	month  	 NN	O
12 	12 	 CD	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
Twelve  	Twelve  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
14.3 	14.3 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
had  	had  	 VBD	O
a  	a  	 DT	O
serious  	serious  	 JJ	O
adverse  	adverse  	 JJ	O
event 	event 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
most  	most  	 RBS	O
common  	common  	 JJ	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
were  	were  	 VBD	O
insomnia  	insomnia  	 NNS	B-NP
( 	( 	 -LRB-	O
17.9 	17.9 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
nausea  	nausea  	 NNS	O
( 	( 	 -LRB-	O
8.3 	8.3 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
akathisia  	akathisia  	 NNS	B-NP
( 	( 	 -LRB-	O
4.8 	4.8 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
anxiety  	anxiety  	 NN	B-NP
( 	( 	 -LRB-	O
4.8 	4.8 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
depression  	depression  	 NN	O
( 	( 	 -LRB-	O
4.8 	4.8 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Body  	Body  	 NN	O
weight  	weight  	 NN	O
values  	values  	 NNS	O
at  	at  	 IN	O
the  	the  	 DT	O
end  	end  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	O
were  	were  	 VBD	O
significantly  	significantly  	 RB	O
higher  	higher  	 RBR	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
baseline 	baseline 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
present  	present  	 JJ	O
study  	study  	 NN	O
demonstrates  	demonstrates  	 VBZ	O
that  	that  	 DT	O
flexible  	flexible  	 JJ	O
dose  	dose  	 NN	O
of  	of  	 IN	O
paliperidone  	paliperidone  	 NN	B-NP
resulted  	resulted  	 VBD	O
in  	in  	 IN	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
improvement  	improvement  	 NN	O
in  	in  	 IN	O
functioning  	functioning  	 VBG	O
and  	and  	 CC	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
symptoms  	symptoms  	 NNS	B-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
recent  	recent  	 JJ	O
onset  	onset  	 NN	B-NP
schizophrenia 	schizophrenia 	 NN	I-NP
.  	.  	 .	O
